The study claimed that ferroptosis scores varied significantly based on patient age, TP53/PIK3CA mutations, PAM50 molecular subtypes, and clinical stages. Assessing ferroptosis activation in BRCA could enhance understanding of tumor microenvironment infiltration and inform more effective immunotherapy strategies. This evidence concerns the gene TP53 and neoplasm.